TY - JOUR
T1 - Evaluation of new anti-infective drugs for the treatment of viral encephalitis
AU - Whitley, R. J.
AU - Lentnek, A.
AU - McCracken, G. H.
AU - Sande, M. A.
AU - Scheld, W. M.
N1 - Funding Information:
Financial support: This work was supported by a contract to the Infectious Diseases Society ofAmerica from the U.S. Food and Drug Administration (no. HHS 223-88-130I). Correspondence: Dr. W. Michael Scheid, Division oflnfectious Diseases, Box 385, University of Virginia, Health Sciences Center, Charlottesville, Virginia 22908.
PY - 1992/11
Y1 - 1992/11
N2 - Viral encephalitis may develop subsequent to viremia, via neuronal spread, or by arthropod vector. Diagnosis often requires invasive studies such as lumbar puncture and brain biopsy. This guideline addresses herpes simplex, rabies, and arbovirus infections of the central nervous system. Clinical trials should be designed according to the availability of approved therapeutic agents. Study designs with an active control (herpesvirus), a placebo control (arbovirus), or no control (rabies virus) are recommended. Outcome should be assessed 4-6 weeks, 4-6 months, and 11-13 months after the completion of therapy. For newborns with encephalitis, outcome should be assessed yearly through the age of 5 years. Assessment of clinical outcome is paramount.
AB - Viral encephalitis may develop subsequent to viremia, via neuronal spread, or by arthropod vector. Diagnosis often requires invasive studies such as lumbar puncture and brain biopsy. This guideline addresses herpes simplex, rabies, and arbovirus infections of the central nervous system. Clinical trials should be designed according to the availability of approved therapeutic agents. Study designs with an active control (herpesvirus), a placebo control (arbovirus), or no control (rabies virus) are recommended. Outcome should be assessed 4-6 weeks, 4-6 months, and 11-13 months after the completion of therapy. For newborns with encephalitis, outcome should be assessed yearly through the age of 5 years. Assessment of clinical outcome is paramount.
UR - http://www.scopus.com/inward/record.url?scp=0026490530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026490530&partnerID=8YFLogxK
U2 - 10.1093/clind/15.Supplement_1.S195
DO - 10.1093/clind/15.Supplement_1.S195
M3 - Article
C2 - 1477230
AN - SCOPUS:0026490530
SN - 1058-4838
VL - 15
SP - S195-S199
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -